{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T03:22:11Z","timestamp":1778988131235,"version":"3.51.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2009,9,20]],"date-time":"2009-09-20T00:00:00Z","timestamp":1253404800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1007\/s11060-009-0010-6","type":"journal-article","created":{"date-parts":[[2009,9,19]],"date-time":"2009-09-19T19:35:44Z","timestamp":1253388944000},"page":"171-185","source":"Crossref","is-referenced-by-count":19,"title":["Bortezomib sensitizes primary human esthesioneuroblastoma cells to TRAIL-induced apoptosis"],"prefix":"10.1007","volume":"97","author":[{"given":"Ronald","family":"Koschny","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidrun","family":"Holland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaromir","family":"Sykora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hande","family":"Erdal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Krupp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfred","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrike","family":"Bockmuehl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Ahnert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Meixensberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Stremmel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henning","family":"Walczak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom M.","family":"Ganten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,9,20]]},"reference":[{"key":"10_CR1","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/hed.20127","volume":"27","author":"EM Diaz Jr","year":"2005","unstructured":"Diaz EM Jr, Johnigan RH 3rd, Pero C, El-Naggar AK, Roberts DB, Barker JL, DeMonte F (2005) Olfactory neuroblastoma: the 22-year experience at one comprehensive cancer center. Head Neck 27:138\u2013149","journal-title":"Head Neck"},{"key":"10_CR2","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/00020840-200304000-00009","volume":"11","author":"PJ Bradley","year":"2003","unstructured":"Bradley PJ, Jones NS, Robertson I (2003) Diagnosis and management of esthesioneuroblastoma. Curr Opin Otolaryngol Head Neck Surg 11:112\u2013118","journal-title":"Curr Opin Otolaryngol Head Neck Surg"},{"key":"10_CR3","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/00029330-200702010-00010","volume":"120","author":"LW Zhang","year":"2007","unstructured":"Zhang LW, Zhang MS, Qi J, Zhang JT, Li GL, Luo L, Wang ZC (2007) Management of intracranial invasive olfactory neuroblastoma. Chin Med J (Engl) 120:224\u2013227","journal-title":"Chin Med J (Engl)"},{"key":"10_CR4","first-page":"503","volume":"35","author":"R Mori","year":"2007","unstructured":"Mori R, Sakai H, Kato M, Hida T, Nakajima M, Fukuda T, Fukunaga M, Abe T (2007) Olfactory neuroblastoma with spinal metastasis: case report. No Shinkei Geka 35:503\u2013508","journal-title":"No Shinkei Geka"},{"key":"10_CR5","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1227\/00006123-199305000-00002","volume":"32","author":"A Morita","year":"1993","unstructured":"Morita A, Ebersold MJ, Olsen KD, Foote RL, Lewis JE, Quast LM (1993) Esthesioneuroblastoma: prognosis and management. Neurosurgery 32:706\u2013714 (discussion 714\u2013715)","journal-title":"Neurosurgery"},{"key":"10_CR6","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1002\/hed.20920","volume":"30","author":"G Bachar","year":"2008","unstructured":"Bachar G, Goldstein DP, Shah M, Tandon A, Ringash J, Pond G, Gullane PJ, Perez-Ordonez B, Gilbert RW, Brown DH, Gentili F, O\u2019Sullivan B, Irish JC (2008) Esthesioneuroblastoma: the Princess Margaret hospital experience. Head Neck 30:1607\u20131614","journal-title":"Head Neck"},{"key":"10_CR7","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S1470-2045(01)00558-7","volume":"2","author":"P Dulguerov","year":"2001","unstructured":"Dulguerov P, Allal AS, Calcaterra TC (2001) Esthesioneuroblastoma: a meta-analysis and review. Lancet Oncol 2:683\u2013690","journal-title":"Lancet Oncol"},{"key":"10_CR8","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s11060-008-9645-y","volume":"90","author":"AB Porter","year":"2008","unstructured":"Porter AB, Bernold DM, Giannini C, Foote RL, Link MJ, Olsen KD, Moynihan TJ, Buckner JC (2008) Retrospective review of adjuvant chemotherapy for esthesioneuroblastoma. J Neurooncol 90:201\u2013204","journal-title":"J Neurooncol"},{"key":"10_CR9","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1006\/excr.2000.4840","volume":"256","author":"H Walczak","year":"2000","unstructured":"Walczak H, Krammer PH (2000) The CD95 (APO-1\/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp Cell Res 256:58\u201366","journal-title":"Exp Cell Res"},{"key":"10_CR10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0378-4274(02)00422-8","volume":"139","author":"M MacFarlane","year":"2003","unstructured":"MacFarlane M (2003) TRAIL-induced signalling and apoptosis. Toxicol Lett 139:89\u201397","journal-title":"Toxicol Lett"},{"key":"10_CR11","doi-asserted-by":"crossref","unstructured":"Wu GS (2009) TRAIL as a target in anti-cancer therapy. Cancer Lett","DOI":"10.1016\/j.canlet.2009.02.029"},{"key":"10_CR12","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2174\/157488709787047530","volume":"4","author":"AC Bellail","year":"2009","unstructured":"Bellail AC, Qi L, Mulligan P, Chhabra V, Hao C (2009) TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. Rev Recent Clin Trials 4:34\u201341","journal-title":"Rev Recent Clin Trials"},{"key":"10_CR13","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s00109-007-0194-1","volume":"85","author":"R Koschny","year":"2007","unstructured":"Koschny R, Walczak H, Ganten TM (2007) The promise of TRAIL-potential and risks of a novel anticancer therapy. J Mol Med 85:923\u2013935","journal-title":"J Mol Med"},{"key":"10_CR14","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/nm735","volume":"8","author":"S Fulda","year":"2002","unstructured":"Fulda S, Wick W, Weller M, Debatin KM (2002) Smac agonists sensitize for Apo2L\/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 8:808\u2013815","journal-title":"Nat Med"},{"key":"10_CR15","first-page":"1362","volume":"7","author":"IF Pollack","year":"2001","unstructured":"Pollack IF, Erff M, Ashkenazi A (2001) Direct stimulation of apoptotic signaling by soluble apo2l\/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells. Clin Cancer Res 7:1362\u20131369","journal-title":"Clin Cancer Res"},{"key":"10_CR16","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1158\/1078-0432.CCR-07-0251","volume":"13","author":"R Koschny","year":"2007","unstructured":"Koschny R, Holland H, Sykora J, Haas TL, Sprick MR, Ganten TM, Krupp W, Bauer M, Ahnert P, Meixensberger J, Walczak H (2007) Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Clin Cancer Res 13:3403\u20133412","journal-title":"Clin Cancer Res"},{"key":"10_CR17","first-page":"135","volume":"7","author":"MB Armstrong","year":"2008","unstructured":"Armstrong MB, Schumacher KR, Mody R, Yanik GA, Opipari AW Jr, Castle VP (2008) Bortezomib as a therapeutic candidate for neuroblastoma. J Exp Ther Oncol 7:135\u2013145","journal-title":"J Exp Ther Oncol"},{"key":"10_CR18","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/hep.21555","volume":"45","author":"R Koschny","year":"2007","unstructured":"Koschny R, Ganten TM, Sykora J, Haas TL, Sprick MR, Kolb A, Stremmel W, Walczak H (2007) TRAIL\/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window. Hepatology 45:649\u2013658","journal-title":"Hepatology"},{"key":"10_CR19","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/hep.20807","volume":"42","author":"TM Ganten","year":"2005","unstructured":"Ganten TM, Koschny R, Haas TL, Sykora J, Li-Weber M, Herzer K, Walczak H (2005) Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL. Hepatology 42:588\u2013597","journal-title":"Hepatology"},{"key":"10_CR20","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cancergencyto.2006.09.024","volume":"173","author":"H Holland","year":"2007","unstructured":"Holland H, Koschny R, Krupp W, Meixensberger J, Bauer M, Kirsten H, Ahnert P (2007) Comprehensive cytogenetic characterization of an esthesioneuroblastoma. Cancer Genet Cytogenet 173:89\u201396","journal-title":"Cancer Genet Cytogenet"},{"key":"10_CR21","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1158\/1078-0432.CCR-05-2635","volume":"12","author":"TM Ganten","year":"2006","unstructured":"Ganten TM, Koschny R, Sykora J, Schulze-Bergkamen H, Buchler P, Haas TL, Schader MB, Untergasser A, Stremmel W, Walczak H (2006) Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin Cancer Res 12:2640\u20132646","journal-title":"Clin Cancer Res"},{"issue":"Suppl 1","key":"10_CR22","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1038\/sj.cdd.4401437","volume":"11","author":"TM Ganten","year":"2004","unstructured":"Ganten TM, Haas TL, Sykora J, Stahl H, Sprick MR, Fas SC, Krueger A, Weigand MA, Grosse-Wilde A, Stremmel W, Krammer PH, Walczak H (2004) Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death Differ 11(Suppl 1):S86\u2013S96","journal-title":"Cell Death Differ"},{"key":"10_CR23","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S1074-7613(00)80211-3","volume":"12","author":"MR Sprick","year":"2000","unstructured":"Sprick MR, Weigand MA, Rieser E, Rauch CT, Juo P, Blenis J, Krammer PH, Walczak H (2000) FADD\/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 12:599\u2013609","journal-title":"Immunity"},{"key":"10_CR24","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0304-3835(02)00020-4","volume":"180","author":"V Strieder","year":"2002","unstructured":"Strieder V, Lutz W (2002) Regulation of N-myc expression in development and disease. Cancer Lett 180:107\u2013119","journal-title":"Cancer Lett"},{"key":"10_CR25","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/00043426-199121000-00015","volume":"13","author":"VL Castaneda","year":"1991","unstructured":"Castaneda VL, Cheah MS, Saldivar VA, Richmond CM, Parmley RT (1991) Cytogenetic and molecular evaluation of clinically aggressive esthesioneuroblastoma. Am J Pediatr Hematol Oncol 13:62\u201370","journal-title":"Am J Pediatr Hematol Oncol"},{"key":"10_CR26","doi-asserted-by":"crossref","first-page":"25020","DOI":"10.1074\/jbc.M202946200","volume":"277","author":"C Xiao","year":"2002","unstructured":"Xiao C, Yang BF, Asadi N, Beguinot F, Hao C (2002) Tumor necrosis factor-related apoptosis-inducing ligand-induced death- inducing signaling complex and its modulation by c-FLIP and PED\/PEA-15 in glioma cells. J Biol Chem 277:25020\u201325025","journal-title":"J Biol Chem"},{"key":"10_CR27","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1172\/JCI34359","volume":"118","author":"A Ashkenazi","year":"2008","unstructured":"Ashkenazi A, Herbst RS (2008) To kill a tumor cell: the potential of proapoptotic receptor agonists. J Clin Invest 118:1979\u20131990","journal-title":"J Clin Invest"},{"key":"10_CR28","first-page":"1122","volume":"63","author":"X Yang","year":"2003","unstructured":"Yang X, Merchant MS, Romero ME, Tsokos M, Wexler LH, Kontny U, Mackall CL, Thiele CJ (2003) Induction of caspase 8 by interferon gamma renders some neuroblastoma (NB) cells sensitive to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but reveals that a lack of membrane TR1\/TR2 also contributes to TRAIL resistance in NB. Cancer Res 63:1122\u20131129","journal-title":"Cancer Res"},{"key":"10_CR29","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1002\/cncr.21323","volume":"104","author":"DM Ashley","year":"2005","unstructured":"Ashley DM, Riffkin CD, Muscat AM, Knight MJ, Kaye AH, Novak U, Hawkins CJ (2005) Caspase 8 is absent or low in many ex vivo gliomas. Cancer 104:1487\u20131496","journal-title":"Cancer"},{"key":"10_CR30","doi-asserted-by":"crossref","first-page":"G129","DOI":"10.1152\/ajpgi.00242.2005","volume":"290","author":"N Ishimura","year":"2006","unstructured":"Ishimura N, Isomoto H, Bronk SF, Gores GJ (2006) Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells. Am J Physiol Gastrointest Liver Physiol 290:G129\u2013G136","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10_CR31","doi-asserted-by":"crossref","first-page":"7434","DOI":"10.1038\/sj.onc.1209719","volume":"25","author":"A Trauzold","year":"2006","unstructured":"Trauzold A, Siegmund D, Schniewind B, Sipos B, Egberts J, Zorenkov D, Emme D, Roder C, Kalthoff H, Wajant H (2006) TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene 25:7434\u20137439","journal-title":"Oncogene"},{"key":"10_CR32","doi-asserted-by":"crossref","first-page":"4953","DOI":"10.1038\/sj.onc.1206656","volume":"22","author":"TR Johnson","year":"2003","unstructured":"Johnson TR, Stone K, Nikrad M, Yeh T, Zong WX, Thompson CB, Nesterov A, Kraft AS (2003) The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. Oncogene 22:4953\u20134963","journal-title":"Oncogene"},{"key":"10_CR33","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.1038\/sj.onc.1210985","volume":"27","author":"P Geserick","year":"2008","unstructured":"Geserick P, Drewniok C, Hupe M, Haas TL, Diessenbacher P, Sprick MR, Schon MP, Henkler F, Gollnick H, Walczak H, Leverkus M (2008) Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- and CD95L-mediated apoptosis. Oncogene 27:3211\u20133220","journal-title":"Oncogene"},{"key":"10_CR34","first-page":"1162","volume":"61","author":"C Hao","year":"2001","unstructured":"Hao C, Beguinot F, Condorelli G, Trencia A, Van Meir EG, Yong VW, Parney IF, Roa WH, Petruk KC (2001) Induction and intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated apotosis in human malignant glioma cells. Cancer Res 61:1162\u20131170","journal-title":"Cancer Res"},{"key":"10_CR35","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.otohns.2008.03.011","volume":"139","author":"JW Kim","year":"2008","unstructured":"Kim JW, Kong IG, Lee CH, Kim DY, Rhee CS, Min YG, Kim CW, Chung JH (2008) Expression of Bcl-2 in olfactory neuroblastoma and its association with chemotherapy and survival. Otolaryngol Head Neck Surg 139:708\u2013712","journal-title":"Otolaryngol Head Neck Surg"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-009-0010-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-009-0010-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-009-0010-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T04:19:27Z","timestamp":1559362767000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-009-0010-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,20]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["10"],"URL":"https:\/\/doi.org\/10.1007\/s11060-009-0010-6","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,20]]}}}